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This was the first case of high-level vanco-
mycin-resistant enterococci with a class A
phenotype isolated from a person in our hospi-
tal or in Ankara, Turkey. To prevent the
organism’s spread, we implemented the recom-
mendations of the Hospital Infection Control
Practices Advisory Committee (5).
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Antimicrobial-Drug Use
and Methicillin-Resistant
Staphylococcus aureus
To the Editor: We read with great interest the
debate on the contribution of antimicrobial
selection pressure to changes in resistance in
Salmonella enterica serovar Typhimurium and
the comparison made with methicillin-resistant
Staphylococcus aureus (MRSA) (1).
We strongly agree with Davis et al. that
infection control practices must play a central
role in successful MRSA control programs.
However, we disagree that the antimicrobial-
drug use practices that contribute to the control
of MRSA have not been scientifically defined. In
a recent review, we identified more than 20
studies on consistent associations, dose-effect
relationships, and concomitant variations, all
supporting a causal relationship between
antimicrobial-drug use and MRSA (2).
Since our review, seven other studies
have reported on the contribution of
antimicrobial-drug use to MRSA colonization
and infection in patients, or to high MRSA rates
in health-care settings (3-9). One study reports
a decrease in the rate of new MRSA cases after
major reduction in antimicrobial-drug use (5).
Although a lower number of discharges and a
shorter hospital stay recorded during the 2-year
postintervention period have been proposed as
other explanations (10), the sharp decrease in
new MRSA cases after the new antibiotic
formulary was implemented (a delay of only a
few months) supports the hypothesis that
reduced antimicrobial pressure contributed to the
decline. Additionally, at the recent 4th Decen-
nial International Conference on Nosocomial
and Healthcare-Associated Infections, at least
five reports addressed either (a) antimicrobial-
drug use and increased MRSA incidence or (b)
antimicrobial-drug use as an independent risk
factor for MRSA acquisition or for persistent
MRSA colonization after mupirocin
treatment (11).
When antimicrobial classes are taken into
account separately, cephalosporins and
fluoroquinolones are often identified as risk
factors for MRSA (2-5,8,11). The mechanisms
that would explain the participation of these
two classes are not fully understood. However,
fluoroquinolones directly enhance the expres-
sion of high-level oxacillin-resistant S. aureus
in vitro (11, p.202). Another recent study shows
that sub-MIC levels of ciprofloxacin increase
adhesion of quinolone-resistant MRSA (12),
which could explain persistent MRSA coloniza-
tion and failure of mupirocin treatment in
patients who received a fluoroquinolone (11,
p.197). MRSA outbreaks in surgical patients
have been controlled by isolating patients and
abandoning third-generation cephalosporins for
surgical prophylaxis (3). As stated by Davis et
al., dissemination of epidemic clones does not
necessarily require antimicrobial selection
pressure; however, the above studies suggest
participation of antimicrobial drugs in MRSA
colonization and outbreaks.
Finally, when citing Dutch infection control
measures as an example of successful control of
MRSA, Davis et al. omit the fact that, among
European countries, the Netherlands has the
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care (13) and one of the lowest in hospitals (14).
Similarly, Nordic European countries report
both very low MRSA prevalence and antimicro-
bial-drug use (13,15). In Denmark, the preva-
lence of MRSA peaked at approximately 18%
among all S. aureus isolates (and approximately
30% among blood isolates only) at the end of the
1960s, then regularly decreased during the 10
following years. This decrease has been attrib-
uted to various interventions, including increas-
ing awareness of hospital hygiene and an
intensive campaign to teach physicians the
principles of prudent antimicrobial-drug use.
Indeed, the decade witnessed a decrease in the
use of streptomycin and tetracycline to which
these MRSA strains were resistant. However,
determining the relative contribution of these
interventions to the disappearance of MRSA
strains from Denmark has not been possible
since all were implemented at approximately
the same time. Since the beginning of the
1980s, the percentage of MRSA has remained
extremely low, and below 1% among blood
S. aureus isolates. Except for a very small
number of localized hospital outbreaks, Danish
MRSA isolates now represent imported cases
from countries with high prevalence. To pre-
serve this low level, patients admitted from
foreign hospitals are isolated and screened for
MRSA carriage. Health-care workers who have
been working in foreign hospitals are also
screened before working in Danish hospitals.
At the same time, both the overall level of
antimicrobial-drug use and the fraction repre-
sented by broad-spectrum antimicrobial drugs,
such as cephalosporins or fluoroquinolones,
remain very low in Danish primary health care
and hospitals, according to the 1999 report by
the Danish Integrated Antimicrobial Resistance
Monitoring and Research Programme (available
from: URL: http://www.svs.dk/dk/Organisation/
z/forsider/Danmap%20forsider.htm).
Additional research is certainly needed to
fully understand the relationship between
antimicrobial use and MRSA. However, the
evidence supports implementation of programs
to control or improve prescriptions when
infection control alone does not control MRSA
or the organization and resources for a “search-
and-destroy” MRSA control strategy are not
available.
Dominique L. Monnet and Niels Frimodt-Møller
Statens Serum Institut, Copenhagen, Denmark
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Lack of Evidence for
Chloramphenicol Resistance
in Neisseria meningitidis, Africa
To the Editor: High-level chloramphenicol
resistance has been reported in 11 epidemio-
logically unrelated Neisseria meningitidis
serogroup B strains in Vietnam and in a single
strain in France, all isolated between 1987 and
1996 (1). Resistance was mediated by a
chloramphenicol acetyltransferase (Cat) en-
coded by a catP gene homologous to
Clostridium perfringens transposon Tn4451.
While used infrequently in industrialized
countries, chloramphenicol is often used to
treat patients with meningococcal disease in
Africa, especially during epidemics, when it
frequently becomes the drug of choice because it
can be administrated intramuscularly (2).
To evaluate the presence of meningococcal
chloramphenicol-resistant isolates in Africa, we
assessed the frequency of the catP gene in 33
N. meningitidis strains of serogroup A from the
collection of the Centers for Disease Control
and Prevention’s Epidemic Investigations
Laboratory. The isolates, selected to give the
maximum geographic and chronological repre-
sentation, were collected during 1963 to 1998
from Chad, Egypt, Gambia, Ghana, Niger,
Nigeria, South Africa, Tanzania, and Uganda,
mostly during outbreaks. Thirteen (39.3%) of
the strains were isolated during the 1990s,
when chloramphenicol resistance was first
described in Vietnam. All isolates were charac-
terized by multilocus enzyme electrophoresis
and represented four major electrophoretic
subgroups (3,4). Chloramphenicol and penicillin
MICs were determined for all isolates, accord-
ing to the recommendations of the National
Committee for Clinical Laboratory Standards,
by the broth microdilution method using
Mueller-Hinton broth with 5% lysed horse blood
incubated in 5% CO2 (5). All isolates were
susceptible to both chloramphenicol (MIC
<2 µg/mL) and penicillin (MIC <0.06 µg/mL). In
addition, we tested all isolates for the presence
of catP by polymerase chain reaction (PCR)
using primers A, B, C, and D (1). Primers A and
B, designed from the sequence of catP, amplify
a 300-bp fragment only in chloramphenicol-
resistant isolates. Primers C and D, designed
on the basis of meningococcal sequences flank-
ing the Tn4451-like insertion, amplify ~1200-bp
fragment in resistant isolates and ~200-bp
fragment in susceptible strains. Strain
LNP13947 (kindly provided by Marc Galimand)
was used as a positive control.
The catP gene was not detected in 32 of 33
N. meningitidis serogroup A strains. One
isolate that was negative with primers C and D
tested positive with primers A and B (M2786,
Nigeria, 1963), which could suggest that catP
was present but in a different location in the
meningococcal genome. However, the chloram-
phenicol MIC of that strain was 2 µg/mL
(susceptible). Repeated attempts to sequence
the A/B amplicon were not successful with
either primers A and B or another set of prim-
ers internal to primers A and B, implying that
only a portion of the catP gene was present or
(even more likely, given the conserved nature
of this gene) that the PCR result was a false
positive.
Chloramphenicol resistance was first
described in meningococcal serogroup B isolates
(1), but only serogroup A strains were included
in this study since A is the most prevalent
serogroup in Africa. (It accounts for most
epidemics in Sub-Saharan regions.) Although
our small sample size limited the chances of
detecting a rare event, the data suggest that
chloramphenicol resistance in Africa is rela-
tively infrequent and that chloramphenicol is
still an appropriate agent to treat meningococ-
cal disease.
The acquisition of plasmids encoding Cat,
which enzymatically inactivate choramphenicol,
is the most common mechanism of resistance in
gram-positive and gram-negative organisms.